2-((2S)-Azepan-2-yl)-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one

ID: ALA4529213

PubChem CID: 136603202

Max Phase: Preclinical

Molecular Formula: C16H19N5OS

Molecular Weight: 329.43

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cc1n[nH]cc1-c1cc2nc([C@@H]3CCCCCN3)[nH]c(=O)c2s1

Standard InChI:  InChI=1S/C16H19N5OS/c1-9-10(8-18-21-9)13-7-12-14(23-13)16(22)20-15(19-12)11-5-3-2-4-6-17-11/h7-8,11,17H,2-6H2,1H3,(H,18,21)(H,19,20,22)/t11-/m0/s1

Standard InChI Key:  FDCAQNSIBAZETI-NSHDSACASA-N

Molfile:  

 
     RDKit          2D

 23 26  0  0  0  0  0  0  0  0999 V2000
    7.0571  -18.9729    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.7665  -18.5643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7665  -17.7430    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0571  -17.3302    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3477  -18.5643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3432  -17.7430    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5605  -17.4948    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    5.0797  -18.1626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5678  -18.8210    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2576  -18.1721    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7736  -17.5096    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9937  -17.7664    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.9982  -18.5878    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.7809  -18.8400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0582  -16.5089    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.0378  -19.6157    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4777  -18.9780    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1486  -18.5153    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9356  -18.7561    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.4098  -19.7967    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.2412  -19.5184    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0144  -20.3530    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8272  -20.2282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  6  4  1  0
  5  1  1  0
  1  2  2  0
  2  3  1  0
  3  4  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9  5  1  0
 10 11  2  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 10  1  0
  8 10  1  0
  4 15  2  0
 14 16  1  0
 17  2  1  6
 17 18  1  0
 18 19  1  0
 17 20  1  0
 19 21  1  0
 20 22  1  0
 21 23  1  0
 22 23  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4529213

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 329.43

Molecular Weight (Monoisotopic): 329.1310

AlogP: 2.89

#Rotatable Bonds: 2

Polar Surface Area: 86.46

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 9.19

CX Basic pKa: 7.80

CX LogP: 1.31

CX LogD: 0.99

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.67

Np Likeness Score: -1.10

References

1. Kurasawa O, Miyazaki T, Homma M, Oguro Y, Imada T, Uchiyama N, Iwai K, Yamamoto Y, Ohori M, Hara H, Sugimoto H, Iwata K, Skene R, Hoffman I, Ohashi A, Nomura T, Cho N..  (2020)  Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent.,  63  (3): [PMID:31895562] [10.1021/acs.jmedchem.9b01427]

Source

Source(1):

• Scientific Literature